QLGN
vs
S&P 500
QLGN
S&P 500
Over the past 12 months, QLGN has underperformed S&P 500, delivering a return of -31% compared to the S&P 500's +13% growth.
Stocks Performance
QLGN vs S&P 500
Performance Gap
QLGN vs S&P 500
Performance By Year
QLGN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Qualigen Therapeutics Inc
Glance View
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
